• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝素酶是乳腺癌免疫浸润和预后的新型生物标志物。

Heparanase is a novel biomarker for immune infiltration and prognosis in breast cancer.

机构信息

Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China.

出版信息

Aging (Albany NY). 2021 Aug 30;13(16):20836-20852. doi: 10.18632/aging.203489.

DOI:10.18632/aging.203489
PMID:34461608
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8436937/
Abstract

Heparanase (HPSE), an endoglycosidase that cleaves heparan sulfate, regulates a variety of biological processes that promote tumor progression. In this study, we analyzed the correlation between HPSE expression and prognosis in cancer patients, using multiple databases (Oncomine, TIMER, PrognoScan, GEPIA, Kaplan-Meier plotter, miner v4.1, DAVID). HPSE expression was significantly increased in bladder, breast, lung, and stomach cancer compared to matched normal tissues. The increased HPSE expression correlated with poor prognosis and increased immune infiltration levels of B cells, CD8+ and CD4+ T cells, macrophages, neutrophils and dendritic cells in bladder and breast cancer. In breast cancer, the high HPSE expression was associated with basal-like subtypes, younger age (0-40), advanced Scarff-Bloom-Richardson grade, Nottingham Prognostic Index and p53 mutation status. In addition, using a mouse model of breast cancer, our data showed that HPSE upregulated IL-10 expression and promoted macrophage M2 polarization and T cell exhaustion. Together, our data provide a novel immunological perspective on the mechanisms underlying breast cancer progression, and indicate that HPSE may serve as a biomarker for immune infiltration and prognosis in breast cancer.

摘要

肝素酶 (HPSE) 是一种能够切割肝素硫酸盐的内切糖苷酶,它调节着多种促进肿瘤进展的生物学过程。在这项研究中,我们使用多个数据库(Oncomine、TIMER、PrognoScan、GEPIA、Kaplan-Meier plotter、miner v4.1、DAVID)分析了 HPSE 表达与癌症患者预后之间的相关性。与配对的正常组织相比,膀胱癌、乳腺癌、肺癌和胃癌中 HPSE 的表达显著增加。HPSE 表达的增加与预后不良以及膀胱癌和乳腺癌中 B 细胞、CD8+和 CD4+T 细胞、巨噬细胞、中性粒细胞和树突状细胞浸润水平的增加相关。在乳腺癌中,高 HPSE 表达与基底样亚型、年轻(0-40 岁)、高级 Scarff-Bloom-Richardson 分级、诺丁汉预后指数和 p53 突变状态有关。此外,使用乳腺癌小鼠模型,我们的数据表明 HPSE 上调了 IL-10 的表达,促进了巨噬细胞 M2 极化和 T 细胞耗竭。总之,我们的数据为乳腺癌进展的机制提供了一个新的免疫学视角,并表明 HPSE 可能作为乳腺癌免疫浸润和预后的标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9386/8436937/7cd4a49d6932/aging-13-203489-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9386/8436937/fcc0861a700c/aging-13-203489-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9386/8436937/976af44b6d87/aging-13-203489-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9386/8436937/0f8dd43b61b9/aging-13-203489-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9386/8436937/752741123927/aging-13-203489-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9386/8436937/7cd4a49d6932/aging-13-203489-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9386/8436937/fcc0861a700c/aging-13-203489-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9386/8436937/976af44b6d87/aging-13-203489-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9386/8436937/0f8dd43b61b9/aging-13-203489-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9386/8436937/752741123927/aging-13-203489-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9386/8436937/7cd4a49d6932/aging-13-203489-g005.jpg

相似文献

1
Heparanase is a novel biomarker for immune infiltration and prognosis in breast cancer.肝素酶是乳腺癌免疫浸润和预后的新型生物标志物。
Aging (Albany NY). 2021 Aug 30;13(16):20836-20852. doi: 10.18632/aging.203489.
2
Analysis of Expression Pattern and Prognostic Value of the Heparanase in Breast Cancer Through CD274/CTLA-4 Immune Checkpoint Proteins.通过 CD274/CTLA-4 免疫检查点蛋白分析肝素酶在乳腺癌中的表达模式和预后价值。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241281285. doi: 10.1177/15330338241281285.
3
LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.LAYN 是胃癌和结肠癌的预后生物标志物,并与免疫浸润相关。
Front Immunol. 2019 Jan 29;10:6. doi: 10.3389/fimmu.2019.00006. eCollection 2019.
4
Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.S1PR1 的预后价值及其与乳腺癌和肺癌免疫浸润的相关性。
BMC Cancer. 2020 Aug 15;20(1):766. doi: 10.1186/s12885-020-07278-2.
5
Integrated analysis identifies TfR1 as a prognostic biomarker which correlates with immune infiltration in breast cancer.整合分析鉴定 TfR1 为一种预后生物标志物,与乳腺癌中的免疫浸润相关。
Aging (Albany NY). 2021 Sep 13;13(17):21671-21699. doi: 10.18632/aging.203512.
6
Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer.DRP1 被鉴定为与乳腺癌免疫浸润相关的预后因素。
Int Immunopharmacol. 2020 Dec;89(Pt B):107078. doi: 10.1016/j.intimp.2020.107078. Epub 2020 Oct 10.
7
NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.NEFM 基因的 DNA 甲基化与乳腺癌的免疫浸润和生存相关。
Clin Epigenetics. 2021 May 17;13(1):112. doi: 10.1186/s13148-021-01096-4.
8
Heat Shock Protein 90 Family Isoforms as Prognostic Biomarkers and Their Correlations with Immune Infiltration in Breast Cancer.热休克蛋白 90 家族亚型作为预后生物标志物及其与乳腺癌免疫浸润的相关性。
Biomed Res Int. 2020 Oct 21;2020:2148253. doi: 10.1155/2020/2148253. eCollection 2020.
9
Is a Prognostic Biomarker and Correlated With Immune Cell Infiltrates in Gastric Cancer.在胃癌中是一种预后生物标志物,并与免疫细胞浸润相关。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820970684. doi: 10.1177/1533033820970684.
10
CMA1 is potent prognostic marker and associates with immune infiltration in gastric cancer.CMA1 是一种强有力的预后标志物,并与胃癌的免疫浸润相关。
Autoimmunity. 2020 Jun;53(4):210-217. doi: 10.1080/08916934.2020.1735371. Epub 2020 Mar 4.

引用本文的文献

1
Current Status of Breast Cancer Immunotherapy and Prognosis-Related Markers.乳腺癌免疫疗法及预后相关标志物的现状
Breast Cancer (Dove Med Press). 2025 Apr 15;17:339-348. doi: 10.2147/BCTT.S506949. eCollection 2025.
2
CD8 T cell exhaustion in the tumor microenvironment of breast cancer.乳腺癌肿瘤微环境中的CD8 T细胞耗竭
Front Immunol. 2024 Dec 9;15:1507283. doi: 10.3389/fimmu.2024.1507283. eCollection 2024.
3
Analysis of Expression Pattern and Prognostic Value of the Heparanase in Breast Cancer Through CD274/CTLA-4 Immune Checkpoint Proteins.

本文引用的文献

1
Heparanase from triple‑negative breast cancer and platelets acts as an enhancer of metastasis.三阴性乳腺癌来源的肝素酶和血小板作为转移增强因子。
Int J Oncol. 2020 Oct;57(4):890-904. doi: 10.3892/ijo.2020.5115. Epub 2020 Aug 27.
2
Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy.骨肉瘤中的肿瘤相关巨噬细胞:从机制到治疗。
Int J Mol Sci. 2020 Jul 23;21(15):5207. doi: 10.3390/ijms21155207.
3
Inhibition of Heparanase Expression Results in Suppression of Invasion, Migration and Adhesion Abilities of Bladder Cancer Cells.
通过 CD274/CTLA-4 免疫检查点蛋白分析肝素酶在乳腺癌中的表达模式和预后价值。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241281285. doi: 10.1177/15330338241281285.
4
Role of a Novel Heparanase Inhibitor on the Balance between Apoptosis and Autophagy in U87 Human Glioblastoma Cells.新型乙酰肝素酶抑制剂对 U87 人神经胶质瘤细胞凋亡与自噬平衡的作用。
Cells. 2023 Jul 19;12(14):1891. doi: 10.3390/cells12141891.
5
Pathophysiology of reinfection by exogenous HSV-1 is driven by heparanase dysfunction.HSV-1 再感染的病理生理学是由乙酰肝素酶功能障碍驱动的。
Sci Adv. 2023 Apr 28;9(17):eadf3977. doi: 10.1126/sciadv.adf3977.
6
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments.肿瘤进展和免疫逃逸中的细胞外基质重塑:从机制到治疗。
Mol Cancer. 2023 Mar 11;22(1):48. doi: 10.1186/s12943-023-01744-8.
7
Heparanase-1: From Cancer Biology to a Future Antiviral Target.乙酰肝素酶-1:从癌症生物学到未来的抗病毒靶点。
Viruses. 2023 Jan 14;15(1):237. doi: 10.3390/v15010237.
8
A narrative review of circulating tumor cells clusters: A key morphology of cancer cells in circulation promote hematogenous metastasis.循环肿瘤细胞簇的叙述性综述:循环中癌细胞的关键形态促进血行转移。
Front Oncol. 2022 Aug 18;12:944487. doi: 10.3389/fonc.2022.944487. eCollection 2022.
肝素酶表达的抑制导致膀胱癌细胞侵袭、迁移和黏附能力的抑制。
Int J Mol Sci. 2020 May 27;21(11):3789. doi: 10.3390/ijms21113789.
4
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.转移性三阴性乳腺癌中阿替利珠单抗联合白蛋白紫杉醇的 III 期 IMpassion130 试验的患者报告结局。
Ann Oncol. 2020 May;31(5):582-589. doi: 10.1016/j.annonc.2020.02.003. Epub 2020 Feb 20.
5
Hinokitiol reduces tumor metastasis by inhibiting heparanase via extracellular signal-regulated kinase and protein kinase B pathway.桧木醇通过细胞外信号调节激酶和蛋白激酶 B 通路抑制乙酰肝素酶减少肿瘤转移。
Int J Med Sci. 2020 Feb 4;17(3):403-413. doi: 10.7150/ijms.41177. eCollection 2020.
6
Pembrolizumab for Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌。
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
7
Heparanase and Chemotherapy Synergize to Drive Macrophage Activation and Enhance Tumor Growth.肝素酶与化疗协同作用驱动巨噬细胞活化并增强肿瘤生长。
Cancer Res. 2020 Jan 1;80(1):57-68. doi: 10.1158/0008-5472.CAN-19-1676. Epub 2019 Nov 5.
8
Heparanase Accelerates Obesity-Associated Breast Cancer Progression.肝素酶加速肥胖相关乳腺癌的进展。
Cancer Res. 2019 Oct 15;79(20):5342-5354. doi: 10.1158/0008-5472.CAN-18-4058. Epub 2019 Sep 3.
9
Breast Cancer: Current Perspectives on the Disease Status.乳腺癌:疾病现状的当前观点。
Adv Exp Med Biol. 2019;1152:51-64. doi: 10.1007/978-3-030-20301-6_4.
10
Leukocyte Heparanase: A Double-Edged Sword in Tumor Progression.白细胞肝素酶:肿瘤进展中的双刃剑。
Front Oncol. 2019 Apr 29;9:331. doi: 10.3389/fonc.2019.00331. eCollection 2019.